Pharmacie Broman SRL
1.1 FTEPharmacie Broman reported total assets of 481,857 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Jul 2026), with 1.1 full-time equivalent.
The score of Pharmacie Broman shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmacie Broman's annual accounts
| 2025 | |
|---|---|
| Net result | 27,988 € |
| Equity | 32,988 € |
| Cash | 42,889 € |
| EBITDA | 84,518 € |
| Total assets | 481,857 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jul 2026
Pharmacie Broman's financial analysis
- Solvency6.8%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmacie Broman
Pharmacie Broman's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1020.136.330
- VAT number
- BE1020136330
- Peppol
- Registered · 0208:1020136330 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Feb 2025
- Registered office
- 6111 Montigny-le-Tilleul
- Size
- Micro · 1.1 FTE
- Latest accounts
- 2025 · filed on 24 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmacie Broman (SRL) has been based in Montigny-le-Tilleul since 2025, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 27,988 € and equity of 32,988 €; its revenue is not published. With 1.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 6.8%, below the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharmacie Broman
Companies in the same business, of comparable size and area, outside its group.
- Apotheek De Vijzel Retail sale of pharmaceutical products Zoersel · balance sheet 509,493 €
- Marc Thoné Retail sale of pharmaceutical products Antwerp · balance sheet 93,815 €
- Medicuro Retail sale of pharmaceutical products Stekene · balance sheet 457,159 €
- Smets Pharma Retail sale of pharmaceutical products Lier · balance sheet 452,862 €
- LNR Retail sale of pharmaceutical products Kasterlee · balance sheet 516,544 €
- P.J. VLEUGELS et Cie Retail sale of pharmaceutical products Frameries · balance sheet 558,880 €
- ML Pharma Retail sale of pharmaceutical products Brussels · balance sheet 573,903 €
- Apham Retail sale of pharmaceutical products Antwerp · balance sheet 398,276 €
Frequently asked questions about Pharmacie Broman
What is the revenue of Pharmacie Broman?
Pharmacie Broman files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmacie Broman?
In Belgium, the VAT number is the company number prefixed with BE: BE1020136330 for Pharmacie Broman, if the company is VAT-registered. Its company number (CBE) is 1020.136.330.
Where is the registered office of Pharmacie Broman?
According to the CBE register, the registered office of Pharmacie Broman is in 6111 Montigny-le-Tilleul.
What is the equity of Pharmacie Broman?
At the close of the 2025 financial year, the equity of Pharmacie Broman amounts to 32,988 €, a solvency of 6.8% of total assets.
How many people work at Pharmacie Broman?
1.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmacie Broman?
The register lists 2 active mandates at Pharmacie Broman. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmacie Broman
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →